Achieve Life Sciences

66 articles with Achieve Life Sciences

• Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking CessationTopline Data Expected in 2Q 2023

  3/29/2023

  Achieve Life Sciences, Inc. today announced that the last study follow-up visit for the last subject enrolled in the Phase 3 ORCA-3 trial has occurred.

• Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023

  3/8/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up visit for the last subject enrolled in the Phase 2 ORCA-V1 trial has occurred.

• Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

  3/3/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced data from the Phase 3 ORCA-2 trial will be presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, being held in San Antonio, TX, March 1-4, 2023.

• Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023

  3/2/2023

  Achieve Life Sciences, Inc. announced it will report its fourth quarter and year-end 2022 financial results and provide an update on the cytisinicline development program on Thursday, March 16, 2023 at 4:30 PM EDT.

• Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023

  2/7/2023

  Achieve Life Sciences, Inc. today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial has completed treatment in the study.

• Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

  2/2/2023

  Achieve Life Sciences, Inc. today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference.

• Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

  1/9/2023

  Achieve Life Sciences, Inc. today announced that the final subject of the Company’s Phase 3 ORCA-3 trial has completed treatment in the study.

• Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

  12/21/2022

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development.

• Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial

  9/27/2022

  Achieve Life Sciences, Inc. today announced that target enrollment of 750 subjects has been reached in the Phase 3 ORCA-3 trial.

• Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

  7/28/2022

  Achieve Life Sciences, Inc. today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

  8/13/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.

• Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen

  8/11/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,083,715 and U.S. Patent No. 11,083,716 covering the novel 3.0 mg three times daily cytisinicline dosing regimen.

• Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update

  8/11/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program.

• Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

  5/4/2021

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that it will report its first quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, May 13, 2021 at 4:30PM EDT.

• Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

  12/7/2020

  Achieve Life Sciences, Inc. announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

• Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update

  11/12/2020

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program.

• Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020

  10/27/2020

  Achieve Life Sciences, Inc. announced the Company will host a Key Opinion Leader virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST.

• Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020

  10/8/2020

  Achieve Life Sciences, Inc. announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October 13th - 16th, 2020.

• Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

  10/7/2020

  Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced initiation of the Phase 3 ORCA-2 clinical trial.